BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/25/2025 1:11:36 AM | Browse: 254 | Download: 421
 |
Received |
|
2025-07-15 09:09 |
|
Peer-Review Started |
|
2025-07-16 00:10 |
|
First Decision by Editorial Office Director |
|
2025-08-19 09:24 |
|
Return for Revision |
|
2025-08-19 09:24 |
|
Revised |
|
2025-08-28 20:36 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-08 09:57 |
|
Second Decision by Editor-in-Chief |
|
2025-10-08 22:38 |
|
Final Decision by Editorial Office Director |
|
2025-10-13 09:45 |
|
Articles in Press |
|
2025-10-13 09:45 |
|
Edit the Manuscript by Language Editor |
|
2025-10-14 10:45 |
|
Typeset the Manuscript |
|
2025-10-17 08:32 |
|
Publish the Manuscript Online |
|
2025-10-25 01:11 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell & Tissue Engineering |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Moaz Safwan, Mariam Safwan Bourgleh, Abdulsalam Al-Ruqi, Omran Shrebaty, Faisal Almujaydil, Basel AlOthaim, Nasser AlRashidi and Khawaja Husnain Haider |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Khawaja Husnain Haider, PhD, Professor, Department of Basic Sciences, Sulaiman Al Rajhi University, PO Box 777, Al Bukairiyah 51941, AlQaseem, Saudi Arabia. khhaider@gmail.com |
| Key Words |
Acute respiratory distress syndrome; COVID-19; Exosomes; Living bio-drugs; Mesenchymal stem cells; Meta-analysis; Network stem cells |
| Core Tip |
Mesenchymal stem cells, as a living bio-drug, are being considered a potential treatment for coronavirus disease 2019-induced acute respiratory distress syndrome due to their immunomodulatory and reparative properties. Our systematic review and meta-analysis, involving 16 randomized controlled trials (n = 1027 acute respiratory distress syndrome patients), is the first study to directly compare the therapeutic benefits of mesenchymal stem cell-based and their derivative exosome-based therapeutic approaches. Although we did not find significant differences in their safety profiles and efficacy, the exosome-based treatment ranked higher in terms of therapeutic benefits in a network meta-analysis, offering practical and logistical advantages. |
| Publish Date |
2025-10-25 01:11 |
| Citation |
Safwan M, Bourgleh MS, Al-Ruqi A, Shrebaty O, Almujaydil F, AlOthaim B, AlRashidi N, Haider KH. Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis. World J Stem Cells 2025; 17(10): 111978 |
| URL |
https://www.wjgnet.com/1948-0210/full/v17/i10/111978.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v17.i10.111978 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
